CSPC Pharmaceutical Group Limited (HKG:1093)
9.89
-0.03 (-0.30%)
Aug 1, 2025, 4:08 PM HKT
AMK Revenue
CSPC Pharmaceutical Group had revenue of 7.01B CNY in the quarter ending March 31, 2025, a decrease of -21.91%. This brings the company's revenue in the last twelve months to 27.04B, down -16.49% year-over-year. In the year 2024, CSPC Pharmaceutical Group had annual revenue of 29.01B, down -7.76%.
Revenue (ttm)
27.04B CNY
Revenue Growth
-16.49%
P/S Ratio
3.90
Revenue / Employee
1.26M CNY
Employees
21,400
Market Cap
113.07B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 29.01B | -2.44B | -7.76% |
Dec 31, 2023 | 31.45B | 513.21M | 1.66% |
Dec 31, 2022 | 30.94B | 3.07B | 11.02% |
Dec 31, 2021 | 27.87B | 2.92B | 11.73% |
Dec 31, 2020 | 24.94B | 2.84B | 12.84% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeOne Medicines | 32.49B |
Hansoh Pharmaceutical Group Company | 13.05B |
Innovent Biologics | 10.03B |
JD Health International | 61.89B |
Akeso | 2.26B |
Sino Biopharmaceutical | 30.72B |
WuXi Biologics | 19.87B |
Sichuan Kelun-Biotech Biopharmaceutical | 2.06B |
CSPC Pharmaceutical Group News
- 3 days ago - Madrigal in-pact with CSPC Pharma for obesity drug license - Seeking Alpha
- 5 weeks ago - Medtide Launches Hong Kong IPO to Boost Weight-loss Business - Benzinga
- 7 weeks ago - AstraZeneca Inks China AI Research Deal For Chronic Diseases - NDTV
- 7 weeks ago - AstraZeneca Inks Research Pact With China's CSPC Pharmaceuticals Focused On AI-Driven Research, Valued Up To $5.33 Billion - Benzinga
- 7 weeks ago - AstraZeneca signs US$5 billion research deal with China’s CSPC - BNN Bloomberg
- 7 weeks ago - CSPC Pharma Pursues Licensing Deals After Lackluster Earnings - Benzinga
- 2 months ago - Chinese biotech’s mega drug-licensing deals with multinationals surge - South China Morning Post
- 9 months ago - CSPC Pharmaceutical Group Limited goes ex dividend tomorrow - Seeking Alpha